logo
  • About Us
    • Company Overview
    • Vision / Mission / Values
    • Leadership
    • Partnering
  • Our Approach
    • Technologies
    • Manufacturing
    • Publications
  • Pipeline
    • Pipeline
      • CAR T-cell therapies 
      • mAb
    • Expanded Access
  • Investors
    • Announcements
    • Corporate Governance
    • Corporate Deck & Presentations
      • Webcasts
      • Presentations
    • Financial Reports
    • Listing Documents
    • IR Contact
  • Newsroom
  • Careers
    • Join Us
  • Contact Us
EN 简
  • About Us
    • Company Overview
    • Vision / Mission / Values
    • Leadership
    • Partnering
  • Our Approach
    • Technologies
    • Manufacturing
    • Publications
  • Pipeline
    • Pipeline
      • CAR T-cell therapies 
      • mAb
    • Expanded Access
  • Investors
    • Announcements
    • Corporate Governance
    • Corporate Deck & Presentations
      • Webcasts
      • Presentations
    • Financial Reports
    • Listing Documents
    • IR Contact
  • Newsroom
  • Careers
    • Join Us
  • Contact Us

Making
Cancer Curable

Our vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.

  • Home -
About CARsgen
We focus on innovative CAR T-cell therapies

We are a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematological malignancies and solid tumors.

Read More
About CARsgen
Pipeline
Pipeline
Innovative and differentiated product pipeline

We develop innovative CAR-T technologies to empower the next generation pipeline products.

Read More
We have built an integrated cell therapy platform
<p>CycloCAR<sup>®</sup></p>

CycloCAR®

Cytokine and Chemokine Loaded CAR

<p>THANK-uCAR<sup>®</sup></p>

THANK-uCAR®

Allogeneic CAR-T platform

<p>LADAR<sup>®</sup></p>

LADAR®

Local Action Driven by Artificial Receptor

News Center
2023-05-18
CARsgen Initiates Phase 2 Clinical Trial for CLDN18.2 CAR T-cell Product CT041 in the U.S.
2023-05-05
CARsgen’s CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer
2023-04-20
CARsgen’s CAR T-cell Candidate CT041 Achieves IND Clearance from the NMPA for the Postoperative Adjuvant Therapy of Pancreatic Cancer
2023-03-22
CARsgen Announced 2022 Annual Results and Business Updates
2023-01-31
CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with PD-L1 Checkpoint Inhibitor to Treat Gastric Cancer
2023-01-20
CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI
Wechat
qr
Twitter Linkedin
  • About Us
  • Company Overview
  • Vision / Mission / Values
  • Leadership
  • Partnering
  • Our Approach
  • Technologies
  • Manufacturing
  • Publications
  • Pipeline
  • Pipeline
  • Expanded Access
  • Investors
  • Announcements
  • Corporate Governance
  • Corporate Deck & Presentations
  • Financial Reports
  • Listing Documents
  • IR Contact
  • Newsroom
  • Careers
  • Join Us
  • Contact Us
Privacy Policy Terms of Use Developed by Euroland IR
Copyright ©2021-2023 CARsgen Therapeutics Holdings Limited